New Products

May 16, 2017

Cynvenio Biosystems ClearID Lung Cancer Test

Cynvenio Biosystems has launched its ClearID Lung Cancer blood test. The 11-gene panel leverages next-generation sequencing technology to identify tumor-related genetic mutations that can be treated with targeted therapies. It identifies ctDNA burden and detects somatic mutations as low as .13 percent with an accuracy of 99.76 percent and a sensitivity of 95.9 percent, the firm said.

May 15, 2017

Empirical Bioscience Plasmid Mini-Prep Kit

Empirical Bioscience recently introduced its Plasmid Mini-Prep Kit. The kit requires only 1 to 3 mL of bacterial culture, and isolates for extraction high-quality plasma or cosmid DNA up to 10 kb in length with yields of up to 20 µg per preparation. The kit also features an integrated pH indicator within the lysis buffer. This indicator changes color to bright yellow when the lysis buffer reaches 7.5, the optimal pH level for DNA binding. If the pH is greater than 7.5 the lysis buffer will appear orange or violet in color indicating that the pH level is inefficient for DNA adsorption, allowing researchers to make adjustments to the mixture for more efficient plasmid isolation.
May 11, 2017

Intermountain's ICG100 ONCO Focus Panel

Intermountain Precision Genomics, a cancer sequencing service provided by Intermountain Healthcare, is now offering the ICG100 ONCO Focus Panel. The next-generation sequencing panel analyzes five genes, KRAS, BRAF, NRAS, EGFR, and KIT, and is a leaner offering than the ICG100 Comprehensive Cancer panel which gauges 162 genes. Intermountain said that the five-gene panel requires as little as 20 nanograms of DNA, or between 5,000 and 8,000 cells, and has a two-day turnaround time, as opposed to the two weeks it takes to get back results from the comprehensive panel. The ICG100 ONCO Focus Panel evaluates genes that are frequently mutated in melanoma, lung, and colon cancers.

May 11, 2017

MDNA Prostate Mitomic Test

Helomics and MDNA Life Sciences have launched MDNA's Prostate Mitomic Test, a liquid biopsy test for early detection of high-grade prostate cancer independent of prostate-specific antigen and age. The test utilizes the company's Mitomic technology platform which exploits unique biologic characteristics of mitochondrial DNA and has a high negative predictive value which can be used to help clinicians determine which patients have a high-grade tumor that requires immediate intervention, the company said. The laboratory-developed test will be available exclusively through Helomics' clinical lab.

May 10, 2017

GenomeDx Decipher Bladder Cancer Classifier

GenomeDx Biosciences launched its Decipher Bladder Cancer Classifier, a clinical assay for subtyping muscle invasive bladder cancer. The commercial launch follows the publication of a study supporting the assay's development and validation. The test is for use by physicians to stratify patients into more accurate risk groups than can be done with traditional diagnostic diagnostic tools. It also is for identifying those patients who are most likely to benefit from additional treatment. 

May 09, 2017

Cancer Genetics Liquid::Lung-cfDNA

Cancer Genetics has launched a new multi-gene liquid biopsy test for lung cancer, based on Thermo Fisher's Oncomine Lung Cell-Free DNA NGS assay. Run on the Ion S5 XL sequencing system, the test provides comprehensive coverage of 11 critical genes and over 150 key hotspots related to lung cancer and has a limit of detection of 0.05 percent.

May 05, 2017

Cerno Bioscience MassWorks Version 5.0

Cerno Bioscience has launched MassWorks Version 5.0. The new version of the software integrates with NIST GC/MS library search and formula look-up, ChemSpider formula look-up, and accurate mass calibration to improve confidence and selectivity of the NIST search. This builds on a system that is well known for enabling routine formula determination through the company's patented TrueCal calibration algorithm, the company said.

May 05, 2017

OncoDNA OncoKDM Platform

OncoDNA has launched OncoKDM, an online platform that allows cancer treatment facilities to interpret their sequencing data alongside other laboratory tests. The platform performs quality control on the raw data, analyses it, and makes the biological and clinical interpretation which result in a detailed, interactive, and customizable report. It can work with many different types of data, including DNA variants, RNA profiles, and protein information, the company said.

May 04, 2017

HTG EdgeSeq PATH Assay

HTG Molecular Diagnostics plans to launch the HTG EdgeSeq PATH Assay for research use only by the end of the second quarter. The assay has been designed for retrospective gene expression profiling to complement traditional immunohistochemistry (IHC) testing. The test assesses mRNA expression of large numbers of biomarkers when formalin-fixed, paraffin-embedded sample availability is limited, the company said. It is designed to detect up to 470 mRNA targets, typically assessed by IHC.

May 03, 2017

Bio-Rad Bio-Plex Pro Human Apolipoprotein Panel

Bio-Rad Laboratories has launched the Bio-Plex Pro Human Apolipoprotein Panel. The 10-plex panel is an expansion of the company's multiplex immunoassay offerings that allows researchers to rapidly detect and quantify key human apolipoproteins associated with cardiovascular disease. The panel includes the largest number of apolipoproteins on the market and includes four targets — Apo C1, Apo D, Apo J, and Apo H — not found on other multiplex panels. It includes high sample detectability, premixed and ready-to-use reagents, and streamlined data analysis, the company said. The panel is for research use only and is compatible with Bio-Plex 200, Bio-Plex 3D, Bio-Plex MAGPIX, and all Luminex platforms.

May 03, 2017

LabCorp VistaSeq Hereditary Cancer Panel

Laboratory Corporation of America has launched 10 new panels to test for risk of specific hereditary cancer syndromes. The number of cancer genes that can be assessed has been increased to 59. The VistaSeq Hereditary Cancer Panel assesses genetic mutations associated with common hereditary cancers, such as breast, ovarian, melanoma, pancreatic, colorectal, endometrial, gastric, and prostate cancers.

May 03, 2017

Chromatrap FFPE ChIP-Seq Kit

Chromatrap has launched an updated version of its FFPE ChIP-seq kit to extract chromatin from formalin fixed paraffin embedded tissue. The new version has a shorter protocol, offers increased chromatin yield/accessible epitopes, and provides greater flexibility in chromatin sample loading for ChIP. The kit contains sufficient Protein A or Protein G based spin-columns, buffers, and reagents to perform 24 chromatin immunoprecipitation assays and up to 10 chromatin preparations. It is also compatible with both qPCR and sequencing as a downstream process.

Apr 27, 2017

True Health Diagnostics genTrue Hereditary Cancer Tests

True Health Diagnostics launched genTrue hereditary cancer tests to identify patients suspected of having heritable cancer syndrome. The tests can be used to determine whether an individual has any of 26 genes associated with an increased risk for breast, colon, prostate, ovarian, endometrial, gastric, melanoma, or pancreatic cancers. 

Apr 26, 2017

TransOmic transEdit-dual CRISPR Combinatorial Gene Knockout Kit

TransOmic is offering a new vector for its transEdit-dual CRISPR system, enabling combinatorial gene knockout to identify functional relationships between genes. The p-Clip-dual vector system can now express two single guide RNAs (sgRNAs) targeting separate genes. The new product builds on the firm's transEdit-dual CRISPR arrayed screening library, which targets 19,000 human genes with vectors expressing two sgRNAs targeting the same gene.

Apr 25, 2017

RTT MolecularDx GeneThink System With HIV-1, Hep B, and Hep C Drug Resistance Tests

RTT MolecularDx has launched its GeneThink drug resistance testing system and drug resistance genotyping tests for HIV-1, hepatitis B virus, and hepatitis C virus.

Apr 24, 2017

Cancer Genetics Complete::IO Immuno-Oncology Panel

Cancer Genetics has launched a new multiplex flow cytometry panel for use in cancer immunotherapy assessment, patient monitoring following treatment, and patient selection and stratification for clinical trials. The Complete::IO assay can help characterize the immune repertoire, immune cell populations, and the tumor microenvironment, the firm said. It detects up to 10 markers on each cell, enabling identification of rare immune cells, including central memory cells, effector cells, effector memory cells, naive CD4+ and CD8+ T cells, regulatory T and B cells, natural killer cells, and plasmacytoid dendritic cells.

Apr 20, 2017

Invitae Immunologic, Metabolic, Newborn Screening Confirmation Panels

Invitae announced it has added 80 new panels and updated 24 panels for the diagnosis of inherited immunologic and metabolic disorders, as well as panels that confirm diagnoses suggested by newborn screening. Some of these offerings include new and updated lysosomal storage disorder panels covering 52 genes; an updated, 90-gene newborn screening confirmation panel; a new panel of 133 genes for diagnosing treatable neurometabolic disorders; a new panel of more than 200 genes linked to primary immunodeficiencies; and a new 46-gene panel for associated monogenic forms of inflammatory bowel disease. Additionally, the firm includes deletion/duplication analysis at no extra charge in an effort to identify between 5 percent and 10 percent of pathogenic variants that are difficult to gauge with next-generation sequencing. 

Apr 20, 2017

Biogazelle mRNA Sequencing

Biogazelle has launched its mRNA sequencing service for human plasma and other bodily fluids. The company uses massively parallel sequencing to quantify and characterize mRNA molecules in low volumes of plasma and can detect between 6,000 and 8,000 genes, it said. This type of analysis provides an order of magnitude more biomarkers than microRNA sequencing, and since it is a liquid biopsy-based technology it allows for serial follow-up of patients to monitor them for disease, the company added.

Apr 12, 2017

Diatech Pharmacogenetics EasyPGX kits, Helix cfDNA kit

Italy's Diatech Pharmacogenetics has launched a line of PCR-based oncology kits. The easyPGX line of PCR kits includes assays to detect KRAS, NRAS, BRAF, EGFR, involved in many solid tumors; DPYD and UGT1A1 variants associated with toxicity upon fluoropyrimidine and irinotecan treatment, respectively; and a thyroid panel. The sensitivity of the assays is as low as 0.5 percent, and the starting material can be DNA extracted from fresh, frozen, and formalin-fixed paraffin-embedded tissues, and plasma; and genomic DNA from whole blood for the DPYD and UGT1A1 kits. Reagents are delivered in eight-well strips pre-loaded with a complete master mix in a dry format that is stable at room temperature. The tests have a turnaround time of less than 3 hours, including deparaffinization and lysis, and require less than 10 minutes of hands-on time. In addition, the company has launched the Helix kit for the extraction of circulating free DNA. This kit can be used with 1 to 5 ml of fresh or frozen plasma and has a turnaround time of less than 3 hours.

Apr 12, 2017

Helomics D-Chip

Helomics launched D-Chip, a searchable bioinformatics platform for mining proprietary multi-omic and clinical data on cancer patients. The technology can be used by diagnostic and drug firms doing biomarker discovery and development, virtual clinical trials, and patient recruitment and selection. 

Apr 12, 2017

Prenetics ONEdna DNA Screening Test Service

Prenetics has launched ONEdna, a DNA screening test service. The screening service provides consumers with a comprehensive view and analysis of an individual's genes along with actionable recommendations, the company said. The results may include insight into health status and risk for disease, optimal diet and nutrition, indications about how a patient may respond to various medications, and identification of the patient's risk of common cancers.

Apr 10, 2017

NuGen Technologies RNA-seq Kits

NuGen Technologies has launched two RNA sequencing kits: Universal Plus mRNA-seq and Trio RNA-seq. The Universal Plus mRNA-seq kit includes the option of eliminating unwanted transcripts after library construction using the company's proprietary AnyDeplete technology. This improves the ability to detect low expressed genes. The kit also enables input in the range of 1 microgram down to 10 nanograms. Trio RNA-seq is a whole-transcriptome kit that is suited for applications with low-abundance transcripts. It incorporates three technologies: single-primer isothermal amplification, DimerFree technology in the library prep step to minimize adapter dimers, and AnyDeplete.

Apr 05, 2017

LifeLabs Genetic Counseling

LifeLabs launched its genetic counseling service for patients in Canada undergoing BRCA1/2 testing, as part of the firm's BRCA testing service. The service is available on a pre- and posttesting basis. The BRCA1/2 testing is provided by LifeLabs' partner, Centogene. 

Apr 05, 2017

Paragon Genomics CleanPlex Target Enrichment Solution

Paragon Genomics has launched its CleanPlex target enrichment solution. The product uses the company's patented amplicon sequencing technology which effectively removes nonspecific PCR products generated during highly multiplexed PCR reactions. This 10-minute digestion step is crucial in achieving high-quality libraries before targeted sequencing, the company said. It removes DNA fragmentation, hybridization, and ligation processes associated with traditional hybrid capture-based methods.

Apr 05, 2017

Bionano Genomics Genomic Analysis Tools Suite

Bionano Genomics has launched a new suite of genomic analysis software, Bionano Access 1.0 and Bionano Solve 3.0. Bionano Access replaces IrysView software for Irys users and centralizes all software needed to generate, edit, analyze, and visualize genome maps. It also comes with a powerful variant annotation pipeline that can filter out common variants based on a database of controls, analyze trios or two samples to identify inherited and de novo structural variants, and visualize and export in a dbVar-compliant VCF file for downstream analysis. Bionano Solve 3.0 is an assembly pipeline within Bionano Access that allows users to run SV analysis or hybrid scaffolding. It also significantly improves the hybrid scaffolding application by integrating two genome maps created separately with different nicking enzymes.

Pages

In Nature this week: paternal age associated with de novo mutations in children, and more.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.